Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

NeoVista prepares to distribute Wet AMD Device in Europe

NeoVista : 02 April, 2008  (Company News)
NeoVista has received approval from BSI Product Services to apply the CE Marking to the company's focal epiretinal brachytherapy device, utilised in a new treatment for wet age-related macular degeneration (AMD).
With CE Marking approval NeoVista now has the ability to distribute and sell its product throughout all EU countries, offering a new treatment option for two million Europeans who are afflicted with wet AMD.

'This is a momentous occasion for NeoVista as a company as we look to expand our operations in the EU with this first essential step towards commercialization,' said John N Hendrick, president and chief executive officer of NeoVista. 'With this approval we hope to bring our treatment to millions of European patients with wet AMD who are seeking a more cost-efficient treatment option that will be potentially as effective as or better than the current standard of care.'

The NeoVista technology delivers beta radiation (using strontium 90) for treatment of wet AMD. Similar in size and appearance to a fountain pen, the surgical device delivers focused beta radiation to leaking blood vessels that affect central vision, without causing damage to the surrounding tissues. As a result of its targeted delivery of radiation, preliminary data show that NeoVista's procedure can be safe for both the physician and the patient and may be able to restore some patients' vision.

The CE Mark is a mandatory European marking for certain product groups (medical devices) to indicate conformity with the essential health and safety requirements outlined in the European Medical Device Directive (legislation passed by the EU). NeoVista received their CE Mark after demonstrating, through audits by BSI, conformance to the Directive and to the internationally recognised quality management system standard for medical devices, ISO 13485:2003.

After being granted permission to affix the CE Mark to the product by an EU-accredited Notified Body such as BSI, NeoVista will now be able to market the product in the following countries that require CE Marking: Austria, Hungary, Poland, Belgium, Iceland, Portugal, Bulgaria, Ireland, Romania, Cyprus, Italy, Slovakia, Czech Republic, Latvia, Slovenia, Denmark, Liechtenstein, Spain, Estonia, Lithuania, Sweden, Finland, Luxembourg, Switzerland, France, Malta, Turkey, Germany, the Netherlands, the United Kingdom, Greece and Norway.

To market the therapy in the USA, NeoVista is currently in the midst of conducting its final Phase 3 clinical trial. The Cabernet (CNV Secondary to AMD Treated with BEta RadiatioN Epiretinal Therapy) trial is a multicenter, randomized, controlled study that is enrolling 450 patients at clinical centers worldwide.

The objective of this study is to establish the safety and effectiveness of the focal epiretinal brachytherapy device in support of a future premarket application (PMA) for this device. Countries participating in the Cabernet trial outside of the USA include the United Kingdom, Austria, Spain, Germany, Switzerland, Israel, Brazil and Peru.
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo